Literature DB >> 23274876

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.

Hiroaki Itamochi1, Misaki Kato, Mayumi Nishimura, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Seiya Sato, Michiko Nonaka, Akiko Kudoh, Naoki Terakawa, Junzo Kigawa, Tasuku Harada.   

Abstract

A new line of human ovarian serous adenocarcinoma cells, TU-OS-4, was established and characterized. The cells showed a short, spindle-shaped morphology and grew in monolayers without contact inhibition while forming an arrangement resembling a jigsaw puzzle. Chromosome numbers ranged from 55 to 73. The proliferation rate was lower than other serous adenocarcinoma cell lines tested (KF, SHIN-3, and SK-OV-3), and the doubling time was 53.3 h. Western blot analysis showed that TU-OS-4 cells overexpressed epidermal growth factor receptor, human epidermal growth factor receptor (HER) 2, and phosphorylated HER2 protein. The IC(50) values to cisplatin, paclitaxel, and lapatinib were 25.8 μM, 686 nM, and 183 nM, respectively. Heterotransplantation in nude mice reflected the original tumor of the cells. These results suggested that this cell line would be useful to study chemoresistant mechanisms and contribute to establishing novel treatment strategies for patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274876     DOI: 10.1007/s13577-012-0048-1

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  13 in total

1.  Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Junzo Kigawa; Toru Sugiyama; Yoshihiro Kikuchi; Mitsuaki Suzuki; Naoki Terakawa
Journal:  Obstet Gynecol       Date:  2002-08       Impact factor: 7.661

2.  ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation.

Authors:  S S Hsieh; C Malerczyk; A Aigner; F Czubayko
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

3.  Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

Authors:  Hiroaki Itamochi
Journal:  World J Biol Chem       Date:  2010-07-26

Review 4.  Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Authors:  Roshan Agarwal; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

Review 5.  Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.

Authors:  Bradley J Monk; Robert L Coleman
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

6.  Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.

Authors:  Jay Sarup; Pei Jin; Lisa Turin; Xiaomei Bai; Malgorzata Beryt; Cathleen Brdlik; Jeffrey N Higaki; Brett Jorgensen; Francis W Lau; Peter Lindley; Jim Liu; Irene Ni; James Rozzelle; Rajendra Kumari; Susan A Watson; Juan Zhang; H Michael Shepard
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells.

Authors:  M T Dimanche-Boitrel; H Pelletier; P Genne; J M Petit; C Le Grimellec; P Canal; C Ardiet; G Bastian; B Chauffert
Journal:  Int J Cancer       Date:  1992-03-12       Impact factor: 7.396

8.  Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.

Authors:  M H Barcellos-Hoff; L J Marton; D F Deen
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

Review 9.  Novel agents on the horizon for cancer therapy.

Authors:  Wen W Ma; Alex A Adjei
Journal:  CA Cancer J Clin       Date:  2009 Mar-Apr       Impact factor: 508.702

10.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more
  2 in total

1.  Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Authors:  Pang-Ning Teng; Nicholas W Bateman; Guisong Wang; Tracy Litzi; Brian E Blanton; Brian L Hood; Kelly A Conrads; Wei Ao; Kate E Oliver; Kathleen M Darcy; William P McGuire; Keren Paz; David Sidransky; Chad A Hamilton; G Larry Maxwell; Thomas P Conrads
Journal:  Hum Cell       Date:  2017-03-01       Impact factor: 4.174

2.  Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs.

Authors:  Hyuna Kim; Youngmi Kim; Hyeonjung Goh; Dooil Jeoung
Journal:  Mol Cells       Date:  2016-02-16       Impact factor: 5.034

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.